- Founded in: 2014
- Number of employees: 15
- Country: France
- Investors: Quadrivium I (Seventure Partners)
- Website: bgene-genetics.com
Which input provides your business model/core technology towards a bio-based economy?
BGene develops the sustainable bio-production of high-value added molecules from abundant, renewable and non-food raw materials using synthetic biology and microbial biodiversity. BGene microbial chassis are in silico designed, robotically constructed to become eco-friendly micro-factories, with the mission to replace petro-sourced or intensive culture processes.
Which market/clients do you address and which short-term/long-term goals do you have?
BGene addresses actors in the sector of flavors and fragrances, willing to shift to environmentally friendly production modes. We design new bioproduction processes for their own molecules, and we also develop our Proprietary Ingredients for this market. In the foreseeable future, the synthesis of these natural molecules will be demonstrated at an industrial scale, from renewable carbon sources.
What makes your approach unique compared to other stakeholders in the field?
BGene develops cutting-edge technologies integrating computer science, biology and fermentation. We can explore data bases to find biological pathways for the synthesis of a molecule, select for a pre-wired microbial chassis, metabolically model it and thus construct a cloning plan. The strains are then robotically constructed and tested in bioreactors in a rational and cost-effective manner.
You can meet BGene at EFIB in Brussels on 30 September – 2 October 2019.